BioConvergence® Presents Case Study on Temperature Controlled Pharmaceutical Products
BioConvergence team members Dêsirêe Valentine and Travis Hudson presented their newest case study (including outcomes of yielding a 99.7 percent excursion-free shipping rate) at the 11th Annual Cold Chain & Temperature Management Global Forum in Chicago, IL earlier this month.
The conference, led by IQPC, focused on shipping regulations, strategies, and trends within the life sciences industry, with special emphasis on maintaining product integrity through temperature management.
"There is plenty of evidence that suggests that a product’s temperature (and the associated fluctuations) can have profound impacts on a product’s stability, and therefore, its therapeutic effectiveness," relates Valentine, Senior Supply Chain Manager at BioConvergence. "Because of this, BioConvergence is committed to keeping our clients’ products within appropriate temperature conditions while at our facility and throughout transit. This year, our team has implemented key changes that have resulted in improved metrics and additional value to clients. In presenting this data at IQPC, we hope that others will utilize this case study to realize similar results and promote improvements throughout the pharmaceutical supply chain."
These improvements, as were discussed in Valentine and Hudson’s presentation, are as follows:
• Yielded a 99.7 percent excursion-free rate
• Decreased Average Days in Transit by over 1 day per shipment
• Reduced Days in Transit (50% reduction in "Delivery Past Qualification" time)
• Improved coordination, both internally and externally
• Established processes for continual improvement moving forward
When asked how BioConvergence achieved these results, Hudson, Associate Process Engineer at BioConvergence, responded, "We began by having a clear picture of the results we wanted to see: improvements to key performance indicators and partnerships, as well as reductions to excursion rates. Next, we began an in-depth analysis of our existing processes and flagged five specific root causes that were interfering with outcomes. After strategically addressing each of these items, we began to see improvements in our metrics. This process has become the standard at BioC in promoting continual improvements."
In addition to presenting this case study, Valentine and Hudson also led a roundtable discussion during the conference entitled, "How to Create Value through Designing and Implementing a Shipping Lane Qualification for High Value Pharmaceutical Products."
To learn more about the framework BioConvergence developed, download the full case study at http://www.bioc.us/iqpc.
BioConvergence is a contract service provider to the life sciences industry, offering outsourcing partnerships for formulation development, testing, production, and supply chain services. Headquartered in Bloomington, Indiana, BioC has over 50 employees with more than four centuries’ worth of combined experience in the pharmaceutical industry. BioC’s unique E-Transparency® System provides transparency and flexibility to its clients, while offering superior, quality-driven outsourcing services. For more information, visit http://www.bioc.us